TSVT News and Press, 2seventy bio Inc. From 06/17/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article is excerpted from Tom Yeung’s Profit & Protection newsletter. To make sure you don’t miss any of Tom’s picks, subscribe to his mailing list here . June’s No. 1 Profit &...

2seventy bio, Inc . (Nasdaq: TSVT) announced today that it will participate in a fireside chat at the Goldman Sachs 43 rd Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 14, 2022 at 3:20pm PT. A live webcast will be available via the Investors...

Reviewing its coverage on biotechs with negative enterprise values, Morgan Stanley says that the number of companies on the list with potential catalysts in 2022 has increased to 27 in May from 20 previously. Adding market capitalization to total debt and deducting cash and cash equivalents, ...

2seventy bio press release (NASDAQ:TSVT): Q1 GAAP EPS of -$3.20. Revenue of $8.43M (-29.2% Y/Y). Ended quarter with $452.5M cash, cash equivalents, and marketable securities; anticipated cash runway into 2025 For further details see: 2seventy bio GAAP EPS of -$3.20, revenue of $8.43M

First patients enrolled in clinical studies in bNHL and AML ABECMA generated $56M U.S. commercial revenue in 1Q; continues to track toward upper end of $250-$300M U.S. ABECMA revenue guidance for 2022 Ended quarter with $452.5M cash, cash equivalents, and marketable se...

bbT369, 2seventy bio’s investigational novel CD79a/CD20 dual targeting CBLB gene edited CAR T cell therapy demonstrates promising anti-lymphoma activity in preclinical models bbT369 is the first novel cell therapy investigated in the clinic that uses 2seventy bio’...

2seventy bio, Inc . (Nasdaq: TSVT) announced today that it will present at the CG Horizons in Oncology Virtual Conference, on the Attacking AML: New Approaches Panel on Thursday, April 14, 2022 at 1:30pm ET. Live webcasts of presentations will be available via the Investors and ...

CRSP needs to make tough decisions regarding the loss of critical CRISPR patents in the US. CRSP differentiates itself by creating allogeneic CAR-T therapy allowing mass production, off-shelf availability, and potentially low production cost. The company is the wealthiest CRISPR b...

2seventy bio press release (NASDAQ:TSVT): Q4 GAAP EPS of -$2.55 beats by $0.80. Revenue of $16.03M (+61.8% Y/Y) beats by $5.64M. For further details see: 2seventy bio GAAP EPS of -$2.55 beats by $0.80, revenue of $16.03M beats by $5.64M

Closed $170M private placement with leading healthcare investors ABECMA generated $158M U.S. commercial revenue in 2021; tracking toward upper end of $250-300M U.S. revenue guidance for 2022 Internal cost reduction measures reduce net cash spend guidance to $190-220M f...